Abstract: The present disclosure provides therapeutic methods of treating a cancer patient with a vinca alkaloide N-oxide and an immune checkpoint inhibitor.
Abstract: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.
Type:
Grant
Filed:
October 25, 2011
Date of Patent:
November 11, 2014
Assignee:
Cascade Prodrug Inc.
Inventors:
John G. Curd, John F. W. Keana, Alshad S. Lalani, Paul B. Westberg, Bradford Goodwin, W. David Henner
Abstract: Disclosed are Mannich base N-oxides of drugs containing acidic N—H groups. Pharmaceutical compositions comprising a therapeutically effective amount of Mannich base N-oxides, or a N-oxide rearrangement product, pharmaceutically acceptable salt or prodrug thereof, are also disclosed. Further, disclosed are methods of using the compounds, alone or in combination with one or more other active agents or treatments.
Type:
Grant
Filed:
September 21, 2009
Date of Patent:
April 2, 2013
Assignee:
Cascade Prodrug Inc.
Inventors:
John F. W. Keana, Paul Westberg, John Curd, Alshad S. Lalani
© 2024 Justia
